Opko Health Inc.  

(Public, NASDAQ:OPK)   Watch this stock  
Find more results for OPK
4.94
+0.07 (1.44%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.80 - 5.01
52 week 4.50 - 12.15
Open 4.83
Vol / Avg. 6.05M/4.86M
Mkt cap 2.76B
P/E     -
Div/yield     -
EPS -0.19
Shares 559.41M
Beta 1.92
Inst. own 24%
Nov 8, 2017
Q3 2017 OPKO Health Inc Earnings Call - Webcast
Nov 8, 2017
Q3 2017 OPKO Health Inc Earnings Release
Sep 27, 2017
OPKO Health Inc at Barrington Research Fall Investment Conference
Sep 26, 2017
OPKO Health Inc at Ladenburg Thalmann Healthcare Conference - Webcast
Sep 25, 2017
OPKO Health Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -16.10% -1.43%
Operating margin -22.12% -6.00%
EBITD margin - 3.47%
Return on average assets -6.20% -0.63%
Return on average equity -8.88% -1.23%
Employees 6,041 -
CDP Score - -

Address

4400 Biscayne Blvd
MIAMI, FL 33137-3212
United States - Map
+1-305-5754138 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Officers and directors

Phillip Frost M.D. Chairman of the Board, Chief Executive Officer
Age: 80
Bio & Compensation  - Reuters
Jane H. Hsiao Ph.D. Vice Chairman of the Board, Chief Technical Officer
Age: 69
Bio & Compensation  - Reuters
Adam E. Logal Chief Financial Officer, Senior Vice President
Age: 39
Bio & Compensation  - Reuters
Steven D. Rubin Esq. J.D. Executive Vice President - Administration, Director
Age: 56
Bio & Compensation  - Reuters
Akhtar Ashfaq M.D. Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division
Bio & Compensation  - Reuters
Thomas Nusbickel Chief Commercial Officer of the Company's Renal Division
Bio & Compensation  - Reuters
Richard M. Krasno Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Richard Alan Lerner M.D. Independent Director
Age: 78
Bio & Compensation  - Reuters
John A. Paganelli Independent Director
Age: 82
Bio & Compensation  - Reuters
Richard C. Pfenniger Jr. Independent Director
Age: 61
Bio & Compensation  - Reuters